Table 1. Clinical and Biological characteristics of the 81 patients at baseline, according to TDF exposure.
| TDF discontinuation n = 28 | TDF continuation n = 31 | No TDF exposure n = 22 | p | |
|---|---|---|---|---|
| Median age [IQR] (years) | 52 [45–63] | 52 [46–57] | 50 [44–58] | 0.65 |
| Male, n (%) | 21 (75.0) | 29 (93.5) | 15 (68.2) | 0.05 |
| Mean bodyweight (SD) (kg) | 63(10) | 66 (12) | 67 (13) | 0.36 |
| AIDS stage, n (%) | 10 (35.7) | 13 (41.9) | 13 (59.1) | 0.24 |
| HIV viral load <20 copies/ml, n (%) | 21 (77.8) | 21 (67.7) | 17 (77.3) | 0.62 |
| CD4 <200 cells/μL, n (%) | 4 (14.3) | 3 (9.7) | 5 (22.7) | 0.42 |
| Anti-HCV+, n (%) | 5 (17.9) | 2 (6.4) | 6 (27.3) | 0.12 |
| Arterial hypertension, n (%) | 4 (14.3) | 4 (12.9) | 2 (9.1) | 0.85 |
| Diabetes, n (%) | 1 (3.6) | 1 (3.2) | 3 (13.6) | 0.23 |
| Protease inhibitor/ritonavir, n (%) | 22 (78.6) | 20 (64.5) | 16 (72.7) | 0.48/0.23* |
| Median duration of TDF therapy [IQ] (months) | 48 [40–67] | 46 [21–69] | 6.5 [0–37] | <0.001/0.43* |
| Median uPCR [IQR] (mg/g) | 322.8 [260.6–445.6] | 255.8 [221.5–335.2] | 277.9[221.2–355.8] | 0.10/0.03* |
| Median uAPR [IQR] | 0.16 [0.11–0.24] | 0.22 [0.19–0.31] | 0.23 [0.13–0.33] | 0.27 |
| Median eGFR, [IQR] (ml/min/1.73m2) | 84.1 [77.8–93.9] | 104.6 [97.3–112.8] | 84.8 [71.8–100.4] | <0.001 |
*comparison between the three groups / comparison TDF discontinuation group versus TDF continuation group
IQR, Interquartile range; SD, Standard deviation; uPCR, Urine protein-to-creatinine ratio; uAPR, Urine albumin-to-protein ratio